Q2 sales rose 4% sequentially but fell 20% year-over-year due to New York Medicaid changes, prompting a successful pivot to the commercial segment, which saw 27% prescription growth in H1. EBIT profitability was achieved, and global expansion continues with launches in China and Korea expected in 2…
Q2 sales rose 4% sequentially but fell 20% year-over-year due to New York Medicaid changes, prompting a successful pivot to the commercial segment, which saw 27% prescription growth in H1. EBIT profitability was achieved, and global expansion continues with launches in China and Korea expected in 2027.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
